Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 787 participants.
Also called NCT03242252
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 787 participants
- Sponsor
- Registry
-
NCT03242252
-
- Other papers using this trial's data
- Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03242252. Randomized; triple masking; primary purpose treatment. Start 2017-08-16 (actual); primary completion 2019-03-25 (actual). Results posted on 2021-06-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
- Acronym
- SOTA-CKD3
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Disease Stage 3
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sotagliflozin
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03242252- Content hash
fc55ad45563d250af070611194c64b6d6fcb56cb3b2a2bb8b5908d3fb9ddaa83